Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sales & Earnings In Brief

This article was originally published in The Tan Sheet

Executive Summary

Merck consumer sales dip: Merck Consumer Care experienced a drop in first-quarter sales compared to a year ago, when, as a unit of Schering-Plough, it benefited from the launch of Claritin Liqui-Gels (1"The Tan Sheet" April 27, 2009). In the first three months of 2010, Whitehouse Station, N.J.-based Merck reported consumer sales of $379 million, down 1.3 percent. Claritin OTC sales sank 26.2 percent to $110 million in the quarter, Merck said May 4. The firm's overall quarterly results reflected effects and costs attributable to the Schering merger; net sales rose 112.1 percent to $11.42 billion, but net income dropped 77.3 percent to $330.2 million. Diluted earnings per share were off 86.6 percent to 9 cents. Merck said it expects in 2012 to begin realizing $3.5 billion in annual synergy savings

You may also be interested in...



In Brief

European trade group touts tradition for herb claims substantiation; Vitacost exits manufacturing; Perrigo launches generic Delsym; Austrian firm offers paper-free blister lid; more news In Brief.

Vitacost.com Turns To Vitamin Shoppe Founder To Right Ship

Vitacost.com CEO Ira Kerker steps down and Jeffrey Horowitz takes the post after logistics challenges and a proxy fight shook up the company's board of directors

Vitacost.com Turns To Vitamin Shoppe Founder To Right Ship

Vitacost.com CEO Ira Kerker steps down and Jeffrey Horowitz takes the post after logistics challenges and a proxy fight shook up the company's board of directors

Related Content

Latest News
See All
UsernamePublicRestriction

Register

PS104097

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel